VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 96 filers reported holding VERVE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 2.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,811,943 | -46.1% | 371,300 | +46.7% | 0.00% | -100.0% |
| Q1 2024 | $3,360,291 | +53.3% | 253,034 | +60.9% | 0.00% | – |
| Q4 2023 | $2,191,940 | -79.1% | 157,241 | -80.2% | 0.00% | -100.0% |
| Q3 2023 | $10,508,895 | -42.6% | 792,526 | -18.8% | 0.00% | -33.3% |
| Q2 2023 | $18,302,400 | +36.0% | 976,128 | +4.6% | 0.00% | 0.0% |
| Q1 2023 | $13,456,269 | -19.1% | 933,167 | +8.6% | 0.00% | 0.0% |
| Q4 2022 | $16,623,624 | -52.1% | 859,102 | -15.0% | 0.00% | -57.1% |
| Q3 2022 | $34,718,000 | +79.8% | 1,010,708 | -20.0% | 0.01% | +75.0% |
| Q2 2022 | $19,305,000 | -63.9% | 1,263,384 | -46.1% | 0.00% | -55.6% |
| Q1 2022 | $53,538,000 | -63.1% | 2,346,047 | -40.4% | 0.01% | -60.9% |
| Q4 2021 | $145,251,000 | -32.0% | 3,939,508 | -14.3% | 0.02% | -36.1% |
| Q3 2021 | $213,551,000 | -8.0% | 4,594,226 | +15.9% | 0.04% | -7.7% |
| Q2 2021 | $232,082,000 | – | 3,965,479 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |